Lexeo Therapeutics Reports Data For LX2006 Gene Therapy In Friedreich Ataxia, Pivotal SUNRISE-FA 2 Study On Track For 2026 Launch, Publishid In The JAMA Cardiology

Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate

Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 50 percent increase over losses of $(0.60) per share from

8-K filing — Lexeo Therapeutics, Inc. (LXEO)

Filed: 2026-08-12 AccNo: 0001193125-26-345722 Size: 18 MB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Lexeo Therapeutics Says FDA Grants RMAT Designation To LX2020 Gene Therapy For PKP2-ACM Based On Interim Phase I/II HEROIC-PKP2 Data

Fermi, Delta Air Lines And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

U.S. stock futures mixed, Dow futures up 100 pts. Fermi Inc (FRMI) shares down 20.4% in pre-market along with other stocks declining.